Navigation Links
PneumRx, Inc. Acquires Key Assets From Broncus
Date:5/21/2012

MOUNTAIN VIEW, Calif., May 21, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has expanded its intellectual property portfolio by acquiring key patents and domain names from Broncus Technologies.

(Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO)

As a result of the acquisition, PneumRx now owns numerous domain names, including emphysema.com, as well as several foundational patents in the emphysema/interventional pulmonology space.

The newly-acquired Intellectual Property is a valuable complement to PneumRx's extensive IP portfolio. It will allow the company to further strengthen its IP position, block competing technologies, and take additional segments of the pulmonary disease market.

PneumRx currently manufactures the RePneu LVRC System, a minimally invasive device intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue (lung volume reduction), restore elastic recoil, and adjust lung compliance. This treatment offers a minimally invasive alternative to lung volume reduction surgery to a broad range of emphysema patients.

The RePneu LVRC has been approved for a 30-site IDE pivotal clinical trial in the United States. The device is offered commercially in Europe, where it received the CE Mark in 2010.

"We are most pleased with the Broncus IP acquisition, which will bolster PneumRx's position as a leader in interventional pulmonology," said Erin McGurk, PneumRx's President and CEO. "PneumRx looks forward to leveraging the newly-acquired IP in pursuit of our mission to provide solutions for the millions of people suffering from pulmonary disease."

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques. It is a privately held company located in Mountain View, California.


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
2. PneumRx, Inc. Raises $33 Million in Capital
3. PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):